Disease which needs to undergo pancreatoduodenectomy (carcinoma of the head of the pancreas, bile duct carcinoma, Papilla Vater carcinoma, duodenal carcinoma, etc.)
Conditions
Interventions
Oral administration of Rikkunshito (2.5g t.i.d) before meals for 21 days. However, Rikkunshito(2.5g t.i.d) were administered as a diluent via enteral feeding tube on postoperative day 1-4.
Sponsors
Sapporo Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients are scheduled to undergo pancreatoduodenectomy. 2) Performance Status(ECOG) of 0 to 1 cases. 3) Age:20<80 4) Sex, inpatient or outpatient: Not matter 5) All patients provided written informed consent before initiation of study-related procedures.
Exclusion criteria
Exclusion criteria: 1) Patient with active double cancer 2) Patient who has been undergoing chemotherapy 3) Patient who receives KAMPO medicine two weeks before treatment of rikkunshito 4) Patients with serious complications (liver, kidney, heart, blood, or metabolic disorders) 5) Patient with serious hypersensitivity 6) Pregnancy or lactation woman. Patients who hope pregnancy during study 7) Patients considered inappropriate by the study investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Occurrence rate of DGE in patients underwent with pancreatoduodenectomy | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Total dietary intake(TDI) after pancreatoduodenectomy 2) Gastrointestinal symptoms after pancreatoduodenectomy 3) The measurement of circulating gastrointestinal hormone(insulin, c-peptide, gastrin, glucagon and ghrelin) | — |
Countries
Japan
Contacts
Public ContactYasutoshi Kimura
Sapporo Medical University Department of Surgery, Surgical Oncology and science
Outcome results
None listed